Jpmorgan Chase & Co »

Inhibrx Biosciences shares owned by Jpmorgan Chase & Co

Quarter-by-quarter ownership of Inhibrx Biosciences shares owned by Jpmorgan Chase & Co from 13F filings

Historical chart of Jpmorgan Chase & Co investment in Inhibrx Biosciences

Tip: Access up to 7 years of quarterly data

All positions including Inhibrx Biosciences held by Jpmorgan Chase & Co consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Inhibrx Biosciences by Jpmorgan Chase & Co

Quarter filed Position value Share count Share price at filing
2024-06-30 $627k 44k 14.17

More positions owned by Jpmorgan Chase & Co

Microsoft Corp Common (MSFT)
Nvidia Corporation Common (NVDA)
Apple Common (AAPL)
Amazon Common (AMZN)
Spdr S&p 500 Etf (SPY)
Meta Platforms Common (META)
Alphabet Common (GOOG)
Eli Lilly & Co Common (LLY)
Unitedhealth Group Common (UNH)
Mastercard Incorporated Common (MA)
Broadcom Common (AVGO)
Alphabet Common (GOOGL)
Vanguard Total Intl Bond Etf Fund (BNDX)
Vanguard S&p 500 Etf idx (VOO)
Ishares Core S&p 500 Etf Fund (IVV)

View all positions for Jpmorgan Chase & Co

Top funds holding Inhibrx Biosciences

Viking Global Investors
Perceptive Advisors
BlackRock
Vanguard Group
Sofinnova Ventures
Slotnik Capital
Alpine Associates Management
Millennium Management
TIG Advisors
Morgan Stanley
Ikarian Capital
Geode Capital Management
Caption Management
Marshall Wace
CSS

View all funds holding Inhibrx Biosciences